AbbVie Inc.
AbbVie Inc. (ABBV) is listed on NYSE and classified in Drug Manufacturers - General, part of the Healthcare sector. It is headquartered in North Chicago, United States and has 57,000 employees. The company is worth $503.96B and trades at 80.6x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $61.16B in fiscal 2025, up 8.6% from the year before. Net income was $4.23B. The share price is within 3% of its 52-week high. It pays a dividend yielding 2.43%, and has raised its annual dividend for 11 years in a row in our records. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Ken Griffin (Citadel Advisors), at $797.64M. In that quarter, 5 of them opened or added to the position and 1 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Articles on this site that cover AbbVie Inc..
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +147.6% over 5Y.
today you would have $2,954.61▲ +195.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 13 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $228.49 | $177.70 | $154.97 | $161.61 | $135.40 | $107.15 | $88.54 | $92.19 | $96.71 | $62.62 | $59.24 | $65.44 | $52.81 | |
| P/E | 25.2x | 96.8x | 74.4x | 57.0x | 24.4x | 21.0x | 39.4x | 16.8x |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Median P/E of 24.3 among peers in the sector.
Median P/E of 25.2 across this company’s own years on record.
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
Dividend growing 5.5% a year against a 7.0% required return, from the stock’s beta.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| JNJJohnson & Johnson | $267.61 | 39.1x | 7.6x | 2.00% | — | $644.91B |
| UNHUnitedhealth Group Inc | $424.98 | 26.8x | 3.7x | 2.18% | 15.77% | $381.46B |
| MRKMerck & Co., Inc. | $147.24 | 116.9x | 8.7x | 2.31% | 6.96% | $363.27B |
| NVSNovartis AG | $156.27 |
| 25.2x |
| 29.3x |
| 17.3x |
| 18.9x |
| 59.5x |
| 20.6x |
| P/S | 4.5x | 6.6x | 5.6x | 5.0x | 4.9x | 4.3x | 4.1x | 3.9x | 4.2x | 5.4x | 3.9x | 4.2x | 5.2x | 4.5x |
| P/B | 22.9x | — | 94.3x | 26.4x | 16.6x | 15.5x | 14.5x | — | — | 30.1x | 21.5x | 24.2x | 59.9x | 18.7x |
| EPS | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 | $2.72 | $5.28 | $3.66 | $3.30 | $3.63 | $3.13 | $1.10 | $2.56 |
| Dividend yield | 3.49% | 2.87% | 3.49% | 3.82% | 3.49% | 3.84% | 4.41% | 4.83% | 3.89% | 2.65% | 3.64% | 3.41% | 2.54% | 3.03% |
| Payout | 85.07% | 277.97% | 259.41% | 217.65% | 85.07% | 80.62% | 173.53% | 81.06% | 98.09% | 77.58% | 62.81% | 64.54% | 150.91% | 62.50% |
| Profit margin | 18.82% | 6.91% | 7.59% | 8.95% | 20.39% | 20.54% | 10.08% | 23.69% | 17.36% | 18.82% | 23.22% | 22.50% | 8.89% | 21.97% |
| ROE | 96.87% | — | 128.66% | 46.94% | 68.60% | 74.91% | 35.30% | — | — | 104.16% | 128.41% | 130.39% | 101.84% | 91.90% |
Median of the years shown; P/E years above 200x are left out.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
5 methods answered, across 4 families.
Room for errors in the reported numbers.
-32.5% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| 23.6x |
| 7.1x |
| 3.03% |
| 30.35% |
| $297.02B |
| AZNAstrazeneca PLC | $172.57 | 25.8x | 5.3x | 1.85% | 21.96% | $267.64B |
| TMOThermo Fisher Scientific Inc | $676.54 | 35.7x | 4.6x | 0.28% | 13.38% | $250.15B |